Clinical trial
Docetaxel With or Without Oblimersen in Treating Patients With…
NCT00085228 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00085228 |
|---|---|
| Title | Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate |
| Official title | Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological, Drug |
| Interventions | oblimersen sodium, docetaxel |
| Enrollment | 116 |
| Start date | Apr 1, 2004 |
| Primary completion | Jan 1, 2006 |
| First posted | Jun 11, 2004 |
| Last update posted | Sep 24, 2012 |
| Countries | Austria, Belgium, Denmark, France, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: